The Best Biotech ETFs to Buy Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector. Kiplinger · Oct 2, 2025
Building AI-ready finance teams, not just AI tools AI is revolutionizing finance by empowering tax teams with technology, skills, and a culture shift. TechRadar · Sep 25, 2025
Do Wall Street Analysts Like Vertex Pharmaceuticals Stock? Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects. Barchart · Aug 25, 2025
These Analysts Slash Their Forecasts On Vertex After Q2 Results Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Benzinga · Aug 7, 2025
Weakness In Vertex Stock Seen As Buying Opportunity Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings. Benzinga · Aug 5, 2025
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday. Benzinga · Aug 5, 2025
Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993 Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report. Benzinga · Aug 4, 2025
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4. Benzinga · Aug 4, 2025
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth. Barchart · Jul 22, 2025
How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks? Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential. Barchart · Jun 9, 2025
Best Biotech Stocks to Buy in 2025 Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. MarketBeat · May 13, 2025
The IT challenge of real-time e-invoicing amid compliance shifts Kathya Capote Peimbert at Vertex explains the business imperative of real-time e-invoicing amid regulatory changes. TechRadar · Apr 29, 2025
Painkillers without the addiction? The new wave of non-opioid pain relief Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced The Guardian - UK · Apr 5, 2025
It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgrade The Shark Vertex DuoClean PowerFin Upright Vacuum is now heavily discounted and brilliant for busy homes Homes & Gardens · Apr 1, 2025
Barchart · Mar 5, 2025 Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector? Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Advnture · Feb 27, 2025 “We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025 2025 brings some exciting new technical runners from the Canadian brand, including a running shoe you can climb in
Barchart · Feb 20, 2025 Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink? Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.
Salon · Feb 10, 2025 Is a new painkiller too good to be true? Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids
The Independent UK · Jan 31, 2025 FDA approves new type of non-opioid pain medication in two decades The new drug will be many times more expensive than a standard opioid option
The Independent UK · Jan 31, 2025 £1.65m gene-editing therapy offers hope of cure for some blood disorder patients The treatment uses gene-editing tool Crispr, which earned its inventors the Nobel Prize in chemistry in 2020.
The Independent UK · Jan 30, 2025 FDA approves new painkiller that shows promise and challenges of opioid alternatives U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids
MarketBeat · Jan 16, 2025 Vertex's Pain Drug: Big Pharma's Next Major Success? Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Barchart · Jan 9, 2025 Vertex Pharmaceuticals Earnings Preview: What to Expect With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.
Fortune · Dec 18, 2024 20 innovative breakthroughs that will transform your health We recognize some of the most staggering, game-changing, life-improving developments of the year.
Benzinga · Dec 9, 2024 Decoding 9 Analyst Evaluations For Vertex During the last three months, 9 analysts shared their evaluations of Vertex (NASDAQ:VERX), revealing diverse outlooks from bullish to bearish.